Search for a rare disease
Other search option(s)
Indomethacin embryofetopathy
Disease definition
Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants.
ORPHA:1909
Classification level: Disorder- Synonym(s):
- Fetal indomethacin syndrome
- Prevalence: Unknown
- Inheritance: Not applicable
- Age of onset: Antenatal, Neonatal
- ICD-10: Q86.8
- OMIM: -
- UMLS: -
- MeSH: -
- GARD: 2303
- MedDRA: -
Additional information
Further information on this disease
Patient-centred resources for this disease
Research activities on this disease
Specialised Social Services
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.